When applied to human skin samples in the lab, the liposomal form of hyaluronic acid triggers skin cells to make more of their own moisturizing substance than regular hyaluronic acid does.
Scientific Claim
Liposomal hyaluronic acid (LPS-HA) is associated with a 3.03-fold increase in HAS-3 mRNA expression in ex vivo human skin after 48 hours of treatment, compared to a 1.31-fold increase with conventional hyaluronic acid, suggesting enhanced local hyaluronan synthesis in the epidermis.
Original Statement
“Ex vivo, LPS-HA enhanced HAS-3 mRNA (3.03 ± 0.19-fold vs. 1.31 ± 0.13-fold with HA; p<0.05) and increased epidermal hyaluronan staining.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
Ex vivo human skin tissue was used, and mRNA levels were measured after treatment. While the design supports association, it cannot prove causation in living humans. 'Associated with' is appropriate.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether LPS-HA causes increased HAS-3 expression and epidermal HA levels in living human skin over time.
Whether LPS-HA causes increased HAS-3 expression and epidermal HA levels in living human skin over time.
What This Would Prove
Whether LPS-HA causes increased HAS-3 expression and epidermal HA levels in living human skin over time.
Ideal Study Design
A double-blind RCT with 50+ adults applying LPS-HA (1%) or HA (1%) daily to forearm skin for 4 weeks, with skin biopsies taken at baseline and week 4 to quantify HAS-3 mRNA and epidermal HA via qPCR and immunofluorescence.
Limitation: Biopsies are invasive and cannot be taken frequently; may not reflect long-term use.
Prospective Cohort StudyLevel 2bWhether daily LPS-HA use correlates with sustained HAS-3 upregulation and improved skin hydration over 3–6 months.
Whether daily LPS-HA use correlates with sustained HAS-3 upregulation and improved skin hydration over 3–6 months.
What This Would Prove
Whether daily LPS-HA use correlates with sustained HAS-3 upregulation and improved skin hydration over 3–6 months.
Ideal Study Design
A 6-month cohort study of 100+ individuals using LPS-HA daily, with quarterly skin biopsies for HAS-3 mRNA and HA staining, and monthly corneometry, adjusting for age and UV exposure.
Limitation: Cannot isolate LPS-HA effect from other skincare habits or environmental factors.
In Vitro Keratinocyte StudyLevel 5In EvidenceWhether LPS-HA directly stimulates HAS-3 expression in human keratinocytes.
Whether LPS-HA directly stimulates HAS-3 expression in human keratinocytes.
What This Would Prove
Whether LPS-HA directly stimulates HAS-3 expression in human keratinocytes.
Ideal Study Design
A replicated in vitro study using HaCaT keratinocytes treated with LPS-HA (0.1–1%) vs. HA (0.1–1%) for 24–72h, measuring HAS-3 mRNA via qPCR and protein via Western blot, with siRNA knockdown of HAS-3 to confirm necessity.
Limitation: Does not reflect skin architecture, barrier function, or systemic influences.
Animal Model StudyLevel 4Whether LPS-HA increases epidermal HA in a living mammalian skin model.
Whether LPS-HA increases epidermal HA in a living mammalian skin model.
What This Would Prove
Whether LPS-HA increases epidermal HA in a living mammalian skin model.
Ideal Study Design
A study in 30+ hairless mice treated topically with LPS-HA or HA daily for 14 days, with skin biopsies analyzed for HAS-3 mRNA, HA content, and epidermal thickness via histology and ELISA.
Limitation: Mouse skin differs significantly from human skin in structure and HA metabolism.
Cross-Sectional StudyLevel 3Whether users of LPS-HA products have higher epidermal HA levels than non-users.
Whether users of LPS-HA products have higher epidermal HA levels than non-users.
What This Would Prove
Whether users of LPS-HA products have higher epidermal HA levels than non-users.
Ideal Study Design
A study comparing HAS-3 expression and HA staining in skin biopsies from 50+ regular LPS-HA users vs. 50+ non-users, matched for age and skin type.
Limitation: Cannot determine if LPS-HA caused the difference or if users have inherently different skin biology.
Evidence from Studies
Supporting (1)
Liposomal Hyaluronic Acid Enhances Skin Permeation and Hydration: Evidence from In Vitro, Ex Vivo, and In Vivo Studies
The study found that skin treated with liposomal hyaluronic acid made 3 times more of a key skin-hydrating molecule than skin treated with regular hyaluronic acid, just like the claim said.